Glossop Paul, Whitlock Gavin, Gibson Karl
Sandexis Medicinal Chemistry Ltd , Innovation House, Discovery Park, Ramsgate Road, Sandwich, Kent, CT13 9ND , UK +44 0 1304 892369 ;
Expert Opin Ther Pat. 2015 Jul;25(7):743-54. doi: 10.1517/13543776.2015.1041923. Epub 2015 May 14.
Asthma is a chronic condition affecting 235 million people worldwide, with prevalence continuing to increase. A significant number of patients have poorly controlled asthma but despite this, a new mechanistic class of small-molecule asthma therapy has not emerged over the past 15 years.
In this article, the authors review the published patent literature from 2013 to 2014 that describes the discovery of novel small-molecule anti-inflammatory agents for the treatment of asthma. This patent analysis was performed using multiple search engines including SciFinder and Free Patents Online.
This review highlights that significant research is still directed towards the development of novel anti-inflammatory agents for the treatment of asthma. Current standard-of-care therapies are given topically to the lung via an inhaled dose, which the authors believe can offer significant advantages in terms of efficacy and therapeutic index, compared with an oral dose. Several of the patents reviewed disclose preferred compounds and data that suggest an inhaled approach is being specifically pursued. The patents reviewed target a wide range of inflammatory pathways, although none have yet delivered an approved novel medicine for asthma; this gives an indication of both the opportunity and challenge involved in such an endeavor.
哮喘是一种慢性疾病，全球有2.35亿人受其影响，且患病率持续上升。相当数量的患者哮喘控制不佳，但尽管如此，在过去15年里尚未出现新的小分子哮喘治疗机制类别。
在本文中，作者回顾了2013年至2014年发表的专利文献，这些文献描述了用于治疗哮喘的新型小分子抗炎药的发现。该专利分析使用了包括SciFinder和在线免费专利在内的多个搜索引擎进行。
本综述强调，仍有大量研究致力于开发用于治疗哮喘的新型抗炎药。目前的标准治疗方法是通过吸入剂量将药物局部施用于肺部，作者认为与口服剂量相比，这在疗效和治疗指数方面具有显著优势。所审查的几项专利披露了优选化合物和数据，表明正在专门探索吸入方法。所审查的专利针对广泛的炎症途径，尽管尚未有针对哮喘的新药获批；这表明了这一努力所涉及的机遇和挑战。
